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Human and simian immunodeficiency-associated retroviruses are extraordinarily complex, containing at
least five genes, tat, art, sor, R, and 3' orf, in addition to the structural genes gag, pol, and env. Recently,
nucleotide sequence analysis of human immunodeficiency virus type 2 (HIV-2) and simian immunodeficiency
virus STVMAC revealed the existence of still another open reading frame, termed X, which is highly conserved
between these two viruses but absent from HIV-1. In this report, we demonstrate for the first time that the X
open reading frame represents a functional retroviral gene in both HIV-2 and SIVMAC and that it encodes a
virion-associated protein of 14 and 12 kilodaltons, respectively. We also describe the production of recombinant
TrpE/X fusion proteins in Escherichia coli and show that sera from some HIV-2-infected individuals specifically
recognize these proteins.
Since the discovery of human immunodeficiency virus
type 1 (HIV-1) as the etiological agent of acquired immuno-
deficiency syndrome in the United States, Europe, Central
Africa, and other areas worldwide (4, 24, 25), additional
retroviruses have been discovered to cause immunodefi-
ciency in human and primate populations. These include
human immunodeficiency virus type 2 (HIV-2), the second
major class of human AIDS retroviruses endemic in West
Africa (3, 7, 8), and the group of simian immunodeficiency
viruses (SIV; for a review, see reference 28), which have
been isolated from rhesus macaques (SIVMAC; 9, 16, 18),
African green monkeys (SIVAGM; 23), and sooty mangabeys
(SIVSMM; 11, 21). HIV-1, HIV-2, and SIV all share similar
ultrastructural, antigenic, and in vitro biological properties,
including a tropism for CD4-bearing target cells and the
ability to exhibit extensive in vitro cytopathicity in appro-
priate target cells (4, 7, 9, 11, 23, 24). Epidemiological
studies, however, indicate that host range, disease associa-
tion, and overall in vivo pathogenic potential can vary
substantially among these viruses and raise the question of
whether strain-specific genetic differences exist among the
major viral groups which are of pathophysiological and
clinical relevance (6, 15, 18a, 22, 24).
Nucleotide sequence comparisons of HIV-1, HIV-2, and
SIVMAC have demonstrated an overall highly conserved
genomic organization, represented by long terminal repeat-
-gag-pol-sor-central region-env-3' orf-long terminal repeat
(1, 5, 12, 20, 26, 27, 30). HIV-2 and SIVMAC are approxi-
mately 75% homologous at the nucleotide sequence level,
and each is approximately 45% similar to HIV-1 (5, 12).
Interestingly, there is an open reading frame in the genomes
of HIV-2 and SIVMAC that is missing in HIV-1. This open
reading frame, termed X, is situated in the central viral
region between the sor and R genes and partially overlaps
the sor open reading frame on its 5' end (5, 12). The deduced
amino acid sequence of X predicts a protein of 112 amino
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acids and 14.5-kilodalton (kDa) calculated molecular mass
which is conserved in 94 of 112 amino acid residues between
HIV-2 and SIVMAC (Fig. 1). In this study, we chemically
synthesized HIV-2 and SIVMAC X-specific oligopeptides,
raised heterologous antisera to these peptides in rabbits, and
expressed the SIVMAC X open reading frame as TrpE fusion
proteins in Escherichia coli. With these reagents, we have
demonstrated that X encodes a novel retroviral protein
uniquely present in HIV-2 and SIVMAC and have provided
evidence for its expression and immunogenicity in vivo.
Two synthetic peptides encompassing 19 residues from
the N terminus of the deduced X amino acid sequences of
HIV-2/ROD (7, 12) and SIVMAC/PK82 (13, 14, 18) (under-
lined in Fig. 1) were synthesized and used to generate rabbit
immune sera. The peptides were prepared by solid-phase
methodology on a peptide synthesizer (model 430-A; Ap-
plied Biosystems) using a paramethylbenzhydrolamine resin
(17). Synthetic peptides were coupled to keyhole limpet
hemocyanin at the carboxy terminus after the addition of
two glycine spacers and a cysteine residue. New Zealand
White rabbits were immunized with 1 mg of keyhole limpet
hemocyanin-coupled peptides emulsified 1:1 in Freund com-
plete adjuvant, boosted twice at 2-week intervals with the
same peptides mixed 1:1 with Freund incomplete adjuvant,
and bled 6 weeks after the first immunization to collect
immune sera. A peptide enzyme-linked immunosorbent as-
say with oligopeptides not coupled to keyhole limpet hemo-
cyanin as the antigens was performed to confirm high-titer
antipeptide antibodies in these sera (10).
The SIVMAC X open reading frame was also expressed as
a fusion protein in E. coli. An XhoII-HindIII fragment
containing the entire SIVMAC X open reading frame minus
the first six nucleotides (SIVMAC clone PKE102; 14) was
subcloned into the bacterial expression vector pATH (29)
immediately adjacent to and in frame with the bacterial trpE
gene (pATH-X, Fig. 2a). E. coli HB101 transformed with
pATH-X was treated in mid-log-phase growth with 3p-indole
acrylic acid to induce the trp operon (22). Cell extracts were
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FIG. 1. Alignment of the deduced X amino acid sequence of
HIV-2 and SIVMAC. The genomic organization of HIV-2 is depicted
as reported by Guyader et al. (12). Shown are eight open reading
frames known to encode HIV proteins as well as the novel X open
reading frame. A comparison of the deduced X amino acid sequence
is shown below for HIV-2 (isolate ROD [12]) and SIVMAC (isolate
PK82 [14, 18]). Vertical bars indicate sequence identity. The first 19
residues (underlined in the HIV-2 and SIVMAC X sequences) repre-
sent the oligopeptides which were synthesized to raise rabbit anti-X
immune sera.
subjected to polyacrylamide gel electrophoresis (19), and a
predominant protein of approximately 50 kDa, consistent
with the predicted molecular mass of a TrpE/X fusion
protein, was identified by Coomassie blue staining of sodium
dodecyl sulfate-polyacrylamide gels (data not shown). A
second plasmid construct was prepared by deleting an
internal NruI-EcoRI fragment in pATH-X, which removed
95% of the trpE coding sequence (Fig. 2a). This plasmid
encoded only 16 amino acid residues derived from the trpE
gene on the N terminus and resulted in an expressed X
fusion protein of 15 kDa (ATrpE/X). Both the TrpE/X fusion
protein and the ATrpE/X fusion protein constituted approx-
imately 20% of the total cellular protein as judged by
Coomassie blue staining of gel-electrophoresed bacterial
lysates (data not shown). Sera from rabbits immunized with
the SIVMAC and HIV-2 X oligopeptides (Fig. 2b, B and D
lanes, respectively) reacted strongly with these lysates on
Western blots (immunoblots) (Fig. 2b, lanes 2 [TrpE/X] and
3 [A&TrpE/X]), but no reactivity was detectable with the
corresponding preimmune sera (Fig. 2b, A and C lanes) or
with lysates of cultures transformed with the nonrecombi-
nant vector (Fig. 2b, lanes 1). An anti-TrpE antiserum, used
for control, detected both the 37-kDa TrpE protein alone as
well as the 50-kDa TrpE/X fusion protein but did not
recognize the 15-kDa ATrpE/X protein (Fig. 2b, E lanes).
To identify the putative X protein in SIVMAC- and HIV-
2-infected cells and cell-free virions, immunoblotting tech-
niques were used to probe viral preparations for reactivity
with the rabbit immune sera. Figure 3a shows the Western
blot patterns of viral preparations from cultures infected
with HIV-1 (lanes 1), HIV-2 (lanes 2), and SIVMAC (lanes 3)
and from mock-infected cells (lanes 4). A polyclonal human
anti-HIV-1 serum (RR lane) and a polyclonal human anti-
HIV-2 serum (ST lanes) were used as controls to confirm the
presence of virus-specific antigens. Probing with the X-
specific rabbit immune sera (anti-SIVMAC, Fig. 3, B lanes;
anti-HIV-2, Fig. 3, D lanes) resulted in the identification of
14- and 12-kDa viral proteins in the HIV-2 and SIVMAC viral
preparations, respectively, but not in similar preparations of
HIV-1 or virally uninfected control cultures. Similar results
were obtained when whole-cell lysates infected with these
viruses were used. No reactivity was detected with the
preimmune sera (A and C lanes). Interestingly, sera from
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FIG. 2. Procaryotic expression of the SIVMAC X protein. (a)
Construction of pATH-X. A procaryotic expression vector, pATH,
(29) was used to express the entire SIVMAC X open reading frame
minus the first two amino acid residues. A 422-base-pair XhoII-
HindIII fragment of SIVMAC clone PKE102 (14) was inserted into
pATH at the BamHI and HindlIl sites as depicted. This placed the
SIVMAC X open reading frame in frame and downstream of the
bacterial trpE gene to allow its expression as a 50-kDa fusion
protein. A unique NruI-EcoRI site was subsequently used to remove
95% of the trpE coding region, leaving only 16 TrpE-derived amino
acids on the 5' end of the expressed SIVMAC X protein. This
construct yielded a smaller fusion protein of 15 kDa. The position of
the trp promoter-operon within the construct is indicated. (b)
Western blot analysis of bacterially expressed SIVMAC X proteins.
E. coli cell lysates transformed with nonrecombinant vector pATH
(lanes 1), pATH-X (lanes 2), and the ATrpE/X construct (lanes 3)
were tested by immunoblot analysis for reactivity to rabbit sera
immunized with SIVMAC and HIV-2 X peptides (B and D lanes,
respectively) as well as to preimmune rabbit sera (A and C lanes). A
50-kDa TrpE/X fusion protein and a 15-kDa ATrpE/X fusion protein
were recognized only by X peptide immune sera. (A smaller band of
approximately 40 kDa probably represents a prematurely truncated
version of the 50-kDa trpE/X protein.) An antiserum raised against
the bacterial trpE gene product (E lanes) was used as a control to
confirm the size of the 50-kDa TrpE/X fusion protein (lane 2) and to
identify the nonrecombinant 37-kDa TrpE protein (lane 1). This
antiserum failed to detect the 15-kDa ATrpE/X protein (lane 3).
Antigen-antibody complexes were detected by using 125I-labeled
protein A.
rabbits immunized with the HIV-2 X peptide recognized
only the homologous HIV-2 X protein (D lanes), while the
SIVMAC X peptide antisera recognized both the HIV-2 and
the SIVMAC X proteins (B lanes). The SIVMAC X protein
appeared to be slightly smaller than the HIV-2 X protein and
was reproducibly present in considerably smaller amounts.
The significance of these differences is presently under
study.
To determine whether the X protein was actually virion
associated, HIV-2 virus was first concentrated by ultracen-
trifugation and then was further purified on a 20 to 60%
continuous sucrose gradient prior to Western blot analysis
(Fig. 3b). HIV-2 X peptide immune sera detected the iden-
tical 14-kDa X protein on immunoblots of banded HIV-2
virions (Fig. 3b, D lane). The intensity of the X-specific band
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FIG. 3. Identification of the HIV-2 and SlVmAc X proteins. (a)
Immunoblot of viral preparations probed with X peptide immune
and preimmune sera. HIV-1 (isolate Illb [24]; lanes 1), HIV-2
(isolate ST [18a]; lanes 2), SIVMAC viral lysates (isolate PK82 [14,
18]; lanes 3), and lysates of uninfected cell culture supernatants
(lanes 4) were separated on a 12.5% polyacrylamide-sodium dode-
cyl sulfate gel, electrophoretically transferred to nitrocellulose, and
reacted with the following sera diluted 1:100 in phosphate-buffered
saline containing 5% nonfat dry milk and 0.1% Tween 20: human
anti-HIV-1-positive serum (RR), human anti-HIV-2-positive serum
(ST), rabbit SIV X peptide preimmune (A) and immune (B) sera, and
rabbit HIV-2 X peptide prei'mmune (C) and immune (D) sera. Bound
antibody was detected by reaction with horseradish peroxidase-
conjugated anti-rabbit and anti-human immunoglobulins with diami-
nobenzidine as a substrate. (b) Immunoblots of sucrose-banded,
purified HIV-2 virions. HIV-2 viral supemnatants (isolate ST [18a])
were clarified by low-speed centrifugation, and virus was pelleted
through a 20% sucrose cushion and then banded in a 20 to 60%o
continuous sucrose gradient. Immunoblots were prepared as de-
scribed previously (3), and identical strips containing purified HIV-2
virions as antigen (2') were reacted with an anti-HIV-2-positive
human serum (ST) and the rabbit HIV-2 X peptide immune sera (D).
(c) Competitive adsorption assay using bacterially expressed SIV-
MAC X protein to adsorb anti-X antibodies. Bacterial lysates of
pATH-X-transformed E. coli immobilized on nitrocellulose were
incubated with SIVMAc and HIV-2 X peptide immune sera (B' and
D', respectively). Preadsorbed sera were subsequently tested by
Western blot analysis for reactivity with preparations of HIV-2
(isolate ST [18a]; lanes 2) and SIVMAC (isolate PK82 [14, 18]; lane 3).
was equal to or slightly greater than those from cell lysates
infected with comparable amounts of HIV-2 (data not
shown). A human serum (Fig. 3b, ST lane) from a healthy
HIV-2-infected individual and the preimmune rabbit antise-
rum failed to detect the X protein in the same antigen
preparation. These data were confirmed with a second
HIV-2 isolate (HIV-2/ROD; 7).
Identification of the 12- and 14-kDa proteins as the virally
encoded X gene products was further established by com-
petitive adsorption assays (Fig. 3c). SIVMAc and HIV-2 X
immune sera were adsorbed with nitrocellulose-immobilized
lysates of E. coli transformed either with the pATH cloning
vector or with the pATH-X recombinant plasmid. Adsorp-
tion of the SIVMAC. X immune sera with the 50-kDa TrpE/X
fusion protein resulted in a complete loss of antibody reac-
tivity with both HIV-2 (Fig. 3c, B' lanes) and S1VMAC viral
preparations. Preadsorption of the same sera with E. ccli
lysates transformed with the pATH vector alone gave hy-
bridization signals equal to that in Fig. 3a, B lanes (not
shown). The reactivity of HIV-2 X peptide antisera was only
slightly diminished by preadsorption with the SIVMAC
TrpE/X fusion protein (Fig. 3c, D' lane), as was expected,
since this antiserum had failed to recognize the heterologous
X protein on previous immunoblots (compare with Fig. 3a, D
lanes). Taken together, these results confirmed the 12- and
14-kDa proteins as the HIV-2 and SIVMAC virally encoded X
proteins.
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FIG. 4. Analysis of human sera for reactivity with the SIVMAC X
proteins expressed in E. coli. Cell lysates transformed with the
pATH vector (lanes 1), pATH-X (lanes 2), and the ATrpE/X
construct (lanes 3) were separated on a 12.5% polyacrylamide-
sodium dodecyl sulfate gel, transferred to nitrocellulose, and ana-
lyzed by immunoblotting for reactivity to four HIV-2 antibody-
positive human sera (a to d), four HIV-1-positive human sera (e to
h), and two normal control sera (i and j). Sera were diluted 1:50 in
phosphate-buffered saline containing 5% nonfat dry milk and 0.1%
Tween 20. Arrows denote the positions of the 50-kDa TrpE/X and
15-kDa ATrpE/X fusion proteins recognized by two of four HIV-2-
positive human sera (a and c). Bound antibody was detected by
1251-labeled protein A.
To evaluate whether the SIVMAC X protein synthesized in
E. ccli could be of diagnostic value, we examined a limited
number of patient and normal control sera for reactivity with
this protein (Fig. 4). Four sera from healthy West African
HIV-2-infected individuals (Fig. 4a to d), four sera from
acquired immunodeficiency syndrome patients seropositive
for HIV-1 (Fig. 4e to h), and two healthy control sera (Fig. 4i
and j) were tested side by side fr reactivity to the 50-kDa
TrpE/X protein (Fig. 4, lanes 2), the 15-kDa ATrpE/X
protein (Fig. 4, lanes 3), and lysates of bacteria transformed
with the nonrecombinant pATH vector (Fig. 4, lanes 1). Out
of four HIV-2 antibody-positive sera tested, two contained
antibodies reactive with both the 50-kDa TrpE/X and 15-kDa
ATrpE/X proteins (Fig. 4a and c). Four HIV-1-positive sera
and two HIV-negative control sera did not react with these
X-specific fusion proteins. Bands corresponding to bacterial
proteins other than the X fusion proteins were also ob-
served, particularly with the West African sera. However,
these were easily distinguishable from X-specific reactivities
by their sizes and occurrence in the control antigen prepa-
rations.
In summary, the data demonstrate that HIV-2 and
SIVMAC viruses encode a novel retroviral protein, termed X,
which is expressed in virus cultures in vitro and in naturally
infected humans. The molecular mass of this protein, 12 to
14 kDa, approximates that calculated from the deduced
amino acid sequence, although the actual structure and
organization of the X gene and its protein and the mode ofX
gene transcription in HIV-2 and SIVMAC viruses cannot be
predicted. Similarly unknown at the present time is the
function of the X protein in the life cycle of HIV-2 and
SIVMAC. The high degree of sequence conservation suggests
a significant function for X in both viruses. The fact that
HIV-1 lacks the X gene entirely, yet causes disease in
infected individuals, implies that X gene expression is not
required for induction of cytopathicity in vitro or in vivo. A
search for X-related protein sequences in the National
Biomedical Research Foundation protein data bank identi-
fied several proline-rich regions, present in retroviral pro-
teins, adenovirus, papillomavirus, human collagen, and a
group of human phosphoproteins, as sharing homology with
the carboxy terminus of the X gene. In addition, a probable
nuclear antigen of Epstein-Barr virus (2) showed 10 of 14
conserved amino acids with a region of X just 5' of the
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polyproline tract (GRG[H/R]G[P/R]GG[W/G]RPG[P/A]P).
The significance of these homologies is under study.
The presence of antibodies specific for X in some HIV-2-
infected individuals demonstrates both its immunogenicity
and in vivo expression. It will be important to determine if
X-specific reagents will be generally useful in distinguishing
between HIV-2 and HIV-1 infections, whether expression of
X in vivo influences viral pathogenesis and clinical outcome,
and whether titers of X-specific antibodies will provide
prognostically important clinical information. The availabil-
ity of X-specific reagents as described in this report should
facilitate experiments addressing these questions.
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